Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -7.50 -6.15% 114.50 113.50 115.00 125.00 110.50 125.00 3,047,321 13:09:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -29.4 -36.8 - 150

4d Pharma Share Discussion Threads

Showing 13026 to 13046 of 13050 messages
Chat Pages: 522  521  520  519  518  517  516  515  514  513  512  511  Older
DateSubjectAuthorDiscuss
27/10/2020
13:26
Devonlad I had a look ealier before adding at the Indicators and the MACD was the most positive of all, at some places were already just crossing "0" not yet convergence blue crossing up red line link [...] advfn does not allow others charts
master rsi
27/10/2020
13:25
I added big block on Thursday so frustrating to see it retrace back so much. Paper profit on Friday was very agreeable.
1airbag
27/10/2020
13:14
Started adding a few long date spread bets and a cash one for a trade, indicators turning. A bit premature because the hourly macd hasn't crossed but it looks like a bowl forming so I took the plunge. Bit of a funny drop given the nasdaq news and that funding is sorted imho, nai dyor.
devonlad
27/10/2020
12:51
I have added because the intraday low 110p was a 61.8% retracement, and have bounce from There
master rsi
27/10/2020
12:26
Looking to add more at these levels but no money until next week
blueblood
27/10/2020
12:25
Merck raises annual profit outlook as Keytruda drives profit beat
jimbo123elf
27/10/2020
11:52
With sitc coming up in a couple of weeks, if this is at 110p come nasdaq listing i will be very surprised and may hang upMy investing boots lol
gooner1886
27/10/2020
11:48
If the price stays around £1.10 when listed on the nasdaq, There's an argument to say that Steve Oliveria will be using his $5m backstop money to increase his holding.
mickinvest
27/10/2020
11:42
stevevic The offer has been underwritten by 4D directors and Steve Oliveira to the tune of $7 million and Whale, LOAC's major shareholder has accepted.
captain james t kirk
27/10/2020
11:40
Agreed shoudnt go below it
gooner1886
27/10/2020
11:40
Devonlad I'm no scientist, I leave that sort of stuff to Spock. However, I would imagine that the differential in patents probably has something to do with the science. Seres have been around since 2008, some time before 4D and they both employ around the same number of people. I do know that regulatory clearance is more complex in the consortia approach, so I suppose it follows that the development is more complex and longer also?
captain james t kirk
27/10/2020
11:38
We don't know. The deal is very confidential and wrapped in NDA's, I have emailed the company and they wont disclose any details, highly secretive but it would be nice to hear something.
devonlad
27/10/2020
11:35
As a matter of interest, how many milestone payments had 4D received and if so how much??
rastamouse
27/10/2020
11:32
If the price offered on nasdaq is approx £1.10 per share then surely the UK price can't go below this otherwise it wont get shareholders approvel in the USA ?
stevevic
27/10/2020
11:30
Fair point Captain. I think that from a discussion we had when Seres announced the phase 3 trials results and the mcap went from $460m to $2bn roughly, DDDD had around 1000 patents granted and another 1000 pending across a wide range of classes. Seres had something like 64 patents granted across a dozen classes. Stand to be corrected on that obviously but it is an example of the massive range of shots on goal we potentially have. No news on the vaccine deal though, I really would love to hear something about that, even if we have hit a target in the process.
devonlad
27/10/2020
11:12
The Stigologist Aren't you clutching at straws again with the Merck/Eisai deal concluded two and a half years ago. Comparing apples and pears so to speak. You have ringed the section where it says launched. That means that Lenvima was already in the market place, selling as an effective cancer therapy in over a dozen jurisdictions. That surely commanded a premium price. You constantly make the same mistake with Seres. They operate in the same space as 4D, namely LBT's, but the science is not the same. 4D are single strain and Seres have enjoyed their success with the consortia of bacteria approach to LBT's. Incidentally, I see that after 12 weeks the efficacy of SER 109 improved over the initial 8 week trial figures for C Diff. So the multi bacteria in a single dose therapy, does appear to work. A good analogy would be shots on goal. The more you have, the more the chance of success.
captain james t kirk
27/10/2020
10:50
Did i say within this week?? You INVEST not TRADING ...unless you are a trader. Give it til January when it list on NASDAQ
deanmatlazin
27/10/2020
10:41
deanmatlazin 23 Oct '20 - 10:44 - 12410 of 12800 £2 next stop chaps = = = = What ever you say Dean.
jenny tulwought
27/10/2020
10:17
Not sure there is a big sell order. Bots are back in control, they will take it up or down as they please, whichever way makes them money. I don't mind a decent drop, clears this bb up from numpties that think an investment is holding a share for more than 24 hours but never make it to a week!
devonlad
27/10/2020
09:41
Vermin more like
trotterstrading
27/10/2020
09:41
rastamouse and now a rastarat - infested with rodents!
2prsimo
Chat Pages: 522  521  520  519  518  517  516  515  514  513  512  511  Older
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201027 13:27:44